Interstitial lung diseases (ILDs) represent a diverse group of over 200 chronic lung conditions characterized by inflammation and fibrosis of the lung interstitium. These disorders, often progressive and with uncertain etiology, pose significant diagnostic and therapeutic challenges to healthcare professionals.
ILDs generally involve alveolar epithelial cells, pulmonary capillary endothelium, basement membrane, perivascular and perilymphatic tissues. The etiology varies, ranging from known causes like occupational exposure, drug toxicity, and connective tissue diseases, to idiopathic forms such as idiopathic pulmonary fibrosis. The pathophysiology is typically characterized by a cycle of injury, inflammation, and repair, leading to fibrosis and architectural distortion.
Patients often present with progressive dyspnea, non-productive cough, and bilateral crackles. High-resolution computed tomography (HRCT) is the cornerstone of diagnosis, showing ground-glass opacities, reticulations, honeycombing, or nodules. Pulmonary function tests often reveal restrictive ventilatory defect and reduced diffusion capacity. In some cases, lung biopsy may be required for definitive diagnosis.
Treatment largely depends on the specific ILD subtype and its cause. In general, management aims at reducing symptoms, improving quality of life, and slowing disease progression. This may include corticosteroids, immunosuppressants, antifibrotic agents, or lung transplantation in severe cases. The prognosis varies widely, with idiopathic forms generally having a poorer outcome.
Understanding the complexities of ILDs is crucial for effective patient management. As healthcare professionals, maintaining an updated knowledge base is fundamental to navigate the diagnostic challenges and therapeutic options, and to provide the best possible care for patients afflicted with these challenging conditions.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation